VMA21 Antikörper
Kurzübersicht für VMA21 Antikörper (ABIN7254226)
Target
Alle VMA21 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Produktmerkmale
- Polyclonal Antibody
-
Aufreinigung
- Antigen affinity purification
-
Immunogen
- Synthetic peptide of human VMA21
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- IHC 1:150-1:500, IF 1: 50-1:200, ELISA 1:5000-1:240000
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 2.6 mg/mL
-
Buffer
- PBS with 0.05 % Sodium azide and 40 % Glycerol, pH 7.4
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
- VMA21 (Vacuolar H+-ATPase Homolog (VMA21))
-
Andere Bezeichnung
- VMA21
-
Hintergrund
- This gene encodes a chaperone for assembly of lysosomal vacuolar ATPase. Required for the assembly of the V0 complex of the vacuolar ATPase (V-ATPase) in the endoplasmic reticulum. Associates with the V0 complex of the vacuolar ATPase (V-ATPase). MEAX is a childhood-onset disease characterized by progressive vacuolation and atrophy of skeletal muscle. It is inherited in recessive fashion, affecting boys and sparing carrier females. Onset is in childhood, and patients exhibit weakness of the proximal muscles of the lower extremities, progressing slowly to involve other skeletal muscle groups over time.
-
UniProt
- Q3ZAQ7
Target
-